Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life sciences company focused on developing a single-molecule protein sequencing and analysis platform aimed at advancing proteomics research. The company went public in June 2021 through a merger with Arya Sciences Acquisition Corp III, a SPAC sponsored by Perceptive Advisors, a life sciences-focused investment firm. Trading under the ticker NAUT since that merger closed, Nautilus operates in the biotechnology and life science instrumentation sector and remains in the development stage as it works toward commercializing its proprietary platform technology. The company filed its most recent annual report on Form 10-K with the SEC on February 26, 2026. For full filing history, deal terms, and real-time SPAC analytics on Nautilus Biotechnology and hundreds of other transactions, create your free account at SpacDesk.